Orchestra BioMed Holdings, Inc.
Orchestra BioMed Holdings, Inc.
Your view on OBIO
Overview
What the company does, where it operates, and who runs it.
About Orchestra BioMed Holdings, Inc.
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- David P. Hochman
- Headquarters
- 150 Union Square Drive, New Hope, PA, US
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- David P. Hochman
- Headquarters
- 150 Union Square Drive, New Hope, PA, US
Orchestra BioMed Holdings, Inc. operates as a biomedical innovation company. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension; and Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of atherosclerotic artery disease.
Its products also comprise FreeHold retractors that are minimally invasive surgical device solutions.
The company has a strategic collaboration with Medtronic for the development and commercialization of BackBeat CNT for the treatment of hypertension in pacemaker-indicated patients; and a strategic partnership with Terumo Corporation for the development and commercialization of Virtue SAB for the treatment of artery disease.
Orchestra BioMed Holdings, Inc. is based in New Hope, Pennsylvania.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
Fair value for Orchestra BioMed Holdings, Inc. from FRC's valuation model, read against the market price. OBIO last traded at $6.01; the estimate is read against that market price. The model runs on every stock on the platform and shows the estimate per share and the date it was calculated. A free account covers 3 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Orchestra BioMed Holdings, Inc.. Starting points for Orchestra BioMed Holdings, Inc.: beta 0.55 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Orchestra BioMed Holdings, Inc.. Orchestra BioMed Holdings, Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Orchestra BioMed Holdings, Inc.. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Analyst Estimates
Analysts' price targets, ratings, and revenue and EPS estimates.
1-Year Price Target
Low
$10.00
Median
$10.00
High
$13.00
Average target · 2 new targets in the last 3 months, average $10.00
Analyst Ratings
- Strong Buy0
- Buy6
- Hold0
- Sell0
- Strong Sell0
Earnings Estimate
| EPS | Current QtrDec 2026 | Next QtrMar 2027 | Current YearFY Dec 2026 | Next YearFY Dec 2027 |
|---|---|---|---|---|
| Avg. estimate | -$0.38 | -$0.36 | -$1.45 | -$1.45 |
| Low estimate | -$0.45 | -$0.41 | -$1.56 | -$1.63 |
| High estimate | -$0.35 | -$0.31 | -$1.38 | -$1.32 |
| No. of analysts | 5 | 2 | 5 | 5 |
| Year-ago EPS | $0.12 | -$0.33 | -$1.11 | — |
| Growth | -418.0% | -8.3% | -30.6% | — |
Revenue Estimate
| Revenue | Current QtrDec 2026 | Next QtrMar 2027 | Current YearFY Dec 2026 | Next YearFY Dec 2027 |
|---|---|---|---|---|
| Avg. estimate | $134429.00 | $96600.00 | $454000.00 | $577286.00 |
| Low estimate | $100821.00 | $87818.00 | $410761.00 | $293535.00 |
| High estimate | $179238.00 | $105381.00 | $540476.00 | $1.25M |
| No. of analysts | 4 | 4 | 6 | 5 |
| Year-ago revenue | $30.92M | $110000.00 | $33.48M | — |
| Growth | -99.6% | -12.2% | -98.6% | — |
Source: Wall Street analysts' published price targets, ratings and estimates, compiled by Financial Modeling Prep from StreetInsider; as of Nov 12, 2026. Not FRC research or a recommendation.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Orchestra BioMed Holdings, Inc.. Orchestra BioMed Holdings, Inc. has reported as a listed company since 2020. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Orchestra BioMed Holdings, Inc. valued side by side against its closest peers. Orchestra BioMed Holdings, Inc. is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
Which funds and firms own the stock.
Which institutions hold Orchestra BioMed Holdings, Inc., and how their positions are changing. At a $361.2M market value, institutional positions materially move Orchestra BioMed Holdings, Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.
Insider Trading
Recent buying and selling by company executives.
Buying and selling by Orchestra BioMed Holdings, Inc. executives and directors. Shares of Orchestra BioMed Holdings, Inc. have traded between $2.20 and $6.30 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Orchestra BioMed Holdings, Inc.. Coverage tracks Orchestra BioMed Holdings, Inc. within Biotechnology (Healthcare). Press releases and market coverage, newest first.
Comments
Comments and replies from FRC members about this company.
No comments yet
Be the first to ask a question or say what you make of Orchestra BioMed Holdings, Inc.